Loading
A phase 2 trial of Pirtobrutinib in chronic lymphocytic leukaemia, run by Loxo Oncology, Inc., now recruiting.
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma is a phase 2 interventional study registered as NCT06588478 by Loxo Oncology, Inc., with 249 participants planned, started 2025-01-03 and due to reach its primary completion in 2028-06. Interventions recorded: Pirtobrutinib.
Shares Pirtobrutinib, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Pirtobrutinib, Eli Lilly (incl. Loxo), Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Pirtobrutinib, Relapsed or refractory chronic lymphocytic leukaemia, Eli Lilly (incl. Loxo), Chronic lymphocytic leukaemia and the tag pipeline.
Shares Pirtobrutinib, Eli Lilly (incl. Loxo), Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.